Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Weizmannia coagulans BC179
- Development stage
- Unknown
- Lead developer
- Wecare Probiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Weizmannia coagulans BC179** is a probiotic bacterial strain, formerly classified as *Bacillus coagulans*, clinically investigated for its protective effects in chronic alcohol consumers. In a randomized, double-blind, placebo-controlled clinical trial, supplementation with BC179 (3 g/day, 1 × 10¹⁰ CFU) for 30 days in adults with a history of long-term alcohol consumption led to significantly reduced blood alcohol concentrations after alcohol ingestion, boosting the activities of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). It also decreased serum markers of hepatic injury (ALP), systemic inflammation (hs-CRP, TNF-α, IL-6), and oxidative stress (CYP2E1, MDA), while upregulating anti-inflammatory and antioxidant markers (IL-10, SOD, glutathione). Metabolomic profiling indicated modulation of taurine and hypotaurine metabolism and downregulation of caffeine pathways. The data suggest the strain exerts its effects through enhancement of alcohol metabolism, anti-inflammatory and antioxidant activity, and targeted host metabolic pathway modulation[2].
- Other names
- Bacillus coagulans BC179
02
Targets
IL10 (Interleukin-10)TNFA (Tumor necrosis factor alpha (soluble))ALDH2 (Mitochondrial Aldehyde Dehydrogenase)IL-6 (Interleukin 6)ADH (Alcohol dehydrogenase family)CYP2E1
Beyond the preview
Go deeper on Weizmannia coagulans BC179.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Weizmannia coagulans BC179.